Vaccine News and Research

Latest Vaccine News and Research

Indian, S. African leaders call for developing countries to work together, invest more in science

India's Prime Minister Manmohan Singh on Tuesday during the launch of the Third World Academy of Sciences meeting (TWAS) in Hyderabad, India, called for developing countries to place greater emphasis on scientific research and application, the Economic Times reports.

22 Oct 2010

NIH awards three new SBIR grants to Taiga

Taiga Biotechnologies, Inc. today announced that the company has received three new Small Business Innovation Research (SBIR) grants from the National Institutes of Health, totaling $1.7 million. This adds to the two previous grants awarded to Taiga for various applications of its proprietary technology platforms, for a total in NIH funding to date of over $2.1 million.

22 Oct 2010

Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease

Idera Pharmaceuticals, Inc. today announced results from its single-dose, dose-escalation Phase 1 clinical trial evaluating the safety and mechanism of action of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for the treatment of autoimmune and inflammatory diseases.

22 Oct 2010

Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, completes recruitment of the first group of patients in its US cervical dysplasia (CIN) phase II study of ADXS11-001 as required for the planned DMSB (safety board) meeting scheduled to be held January 11, 2011.

22 Oct 2010

Oral cancer linked to oral sex: Study

Swedish researchers have found that the Human papillomavirus (HPV) that causes cervical cancer in women is also a risk factor for oropharyngeal squamous cell carcinoma (OSCC) or oral and throat cancer in men even if they do not smoke or consume alcohol.

21 Oct 2010

Baxter third quarter net income increases 12% to $595 million

Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.

From Baxter International Inc. 21 Oct 2010

Research identifies key regulators that control transmission of malaria parasite

Scientists at The University of Nottingham and the Wellcome Trust Sanger Institute near Cambridge have pin-pointed the 72 molecular switches that control the three key stages in the life cycle of the malaria parasite and have discovered that over a third of these switches can be disrupted in some way.

21 Oct 2010

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

Intercell AG and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug, nitazoxanide, during the first half of 2011.

21 Oct 2010

New immunoSEQ bioinformatics software platform helps monitor adaptive immune system

Adaptive TCR Technologies, a biotech firm based in Seattle, WA, announced today the release of its immunoSEQ profiling service and immunoSEQ Analyzer bioinformatics software platform. Together, these tools provide researchers and clinicians the ability to profile and monitor the adaptive immune system at a level of detail that has never before been possible.

21 Oct 2010

SciDev.Net examines plans for India-S. Africa HIV vaccine research project

SciDev.Net reports on an HIV vaccine research collaboration between researchers from India and South Africa to launch by the end of 2010.

21 Oct 2010

Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment

Alexion Pharmaceuticals, Inc. today announced that its two open-label Phase 2 studies investigating eculizumab (Soliris) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) have met the primary and key secondary endpoints with high clinical and statistical significance, in interim analyses.

21 Oct 2010

IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from seven hospital Institutional Review Boards in India to begin enrollment of subjects for a Phase III clinical trial of Multikine, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.

21 Oct 2010

Study: Flu vaccine is money loser for doctors paid by Medicaid

More poor children would get the flu vaccine if Medicaid increased the reimbursement to doctors for giving the shot, according to a new study published in the journal Pediatrics.

21 Oct 2010

LANL's researcher to implement first human trial of mosaic HIV vaccine candidate

Los Alamos National Laboratory researcher Bette Korber is part of an international team of investigators working to design and implement the first human trial of a mosaic HIV vaccine candidate. The vaccine represents a novel strategy for fighting the virus that causes AIDS by attempting to address one of the most daunting challenges in HIV vaccine design: the virus's extensive genetic diversity.

20 Oct 2010

RWV bioreactor creates 3-D cell culture models

The cells and tissues in our bodies grow, develop and interact in a highly complex, three-dimensional world. Likewise, the various microbial pathogens that invade our bodies and cause infectious disease interact with this complex 3-D tissue milieu. In the current issue of the journal Nature Reviews Microbiology, researcher Cheryl Nickerson and her team at the Biodesign Institute at Arizona State University highlight an innovative approach for studying cells in 3-D.

20 Oct 2010

National Pap Test Campaign for cervical cancer diagnosis

The Federation of Medical Women of Canada (FMWC) and the Society of Obstetricians and Gynaecologists of Canada (SOGC) are ready to launch this year's National Pap Test Campaign, to take place during National Cervical Cancer Awareness Week. From October 24th to 30th, over 100 health-care professionals across Canada are taking a stand against cervical cancer by hosting public Pap test clinics in their community.

20 Oct 2010

Adamis acquires prostrate drug candidates from Colby Pharmaceuticals

Adamis Pharmaceuticals Corporation today announced the completion of the acquisition from Colby Pharmaceuticals of the remaining exclusive license agreements relating to two drug product candidates for the treatment of prostate cancer (PCa).

20 Oct 2010

MannKind begins MKC1106-MT Phase 2 trial for advanced melanoma

MannKind Corporation today announced the first patient has been dosed in a phase 2 clinical trial of the novel, investigational cancer vaccine MKC1106-MT. As a part of MannKind's cancer immunotherapy program, this phase 2 study will evaluate the safety, tolerability, immune response and clinical response of MKC1106-MT in patients with advanced melanoma.

20 Oct 2010

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third quarter of 2009. Operational results increased 0.1% and the negative impact of currency was 0.8%. Domestic sales declined 2.5%, while international sales increased 1.1%, reflecting operational growth of 2.6% and a negative currency impact of 1.5%.

19 Oct 2010

Health care reform will lead more people to seek cancer prevention and risk-reduction services

More people will likely seek cancer prevention and risk-reduction services as a result of health care reform, say experts at The University of Texas MD Anderson Cancer Center.

19 Oct 2010

Vaccine News and Research

Latest Vaccine News and Research

Indian, S. African leaders call for developing countries to work together, invest more in science

NIH awards three new SBIR grants to Taiga

Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease

Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

Oral cancer linked to oral sex: Study

Baxter third quarter net income increases 12% to $595 million

Research identifies key regulators that control transmission of malaria parasite

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

New immunoSEQ bioinformatics software platform helps monitor adaptive immune system

SciDev.Net examines plans for India-S. Africa HIV vaccine research project

Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment

IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer

Study: Flu vaccine is money loser for doctors paid by Medicaid

LANL's researcher to implement first human trial of mosaic HIV vaccine candidate

RWV bioreactor creates 3-D cell culture models

National Pap Test Campaign for cervical cancer diagnosis

Adamis acquires prostrate drug candidates from Colby Pharmaceuticals

MannKind begins MKC1106-MT Phase 2 trial for advanced melanoma

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Health care reform will lead more people to seek cancer prevention and risk-reduction services

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in